Dolutegravir

Janessa Smith, Pharm.D. BCPS, Paul A. Pham, Pharm.D., BCPS
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID
Dolutegravir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

Tivicay: Treatment of HIV-1 infection in combination with other ARV agents in adults and children weighing ≥30 kg

Triumeq: Treatment of HIV-1 infection in adults and children weighing ≥40 kg

Juluca: Treatment of HIV-1 infection as a complete regimen for adult patients already virologically suppressed on stable ART for 6 months and no known resistance to dolutegravir or rilpivirine

NON-FDA APPROVED USES

Non-occupational post-exposure prophylaxis (nPEP) in combination with other ARV agents

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

Tivicay: Treatment of HIV-1 infection in combination with other ARV agents in adults and children weighing ≥30 kg

Triumeq: Treatment of HIV-1 infection in adults and children weighing ≥40 kg

Juluca: Treatment of HIV-1 infection as a complete regimen for adult patients already virologically suppressed on stable ART for 6 months and no known resistance to dolutegravir or rilpivirine

NON-FDA APPROVED USES

Non-occupational post-exposure prophylaxis (nPEP) in combination with other ARV agents

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: September 13, 2018